- Home
- NPV vs MSLE Comparison
NPV vs MSLE Comparison
Compare NPV & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NPV | MSLE |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.3M | 186.9M |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NPV | MSLE |
|---|---|---|
| Price | $9.60 | $6.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.17 |
| AVG Volume (30 Days) | ★ 125.2K | 64.2K |
| Earning Date | 01-01-0001 | 11-15-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.05 | $5.44 |
| 52 Week High | $11.81 | $13.39 |
Technical Indicators
Market Signals| Indicator | NPV | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 48.56 | 32.08 |
| Support Level | $9.05 | $5.52 |
| Resistance Level | $11.61 | $10.58 |
| Average True Range (ATR) | 0.15 | 0.58 |
| MACD | 0.07 | -0.02 |
| Stochastic Oscillator | 67.86 | 7.39 |
Price Performance
Historical ComparisonAbout NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. The company mostly invests in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities, Housing/Multifamily, Transportation, and Others.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.